Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Lena van der Wekken-Pas; Fabian Weiss; Charlotte Simon-Zuber; Rena Sebisch; Carmen Wiese; Elisabeth van Leeuwen; David Burger; Angela Colbers

doi:10.1093/cid/ciae242

Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Lena van der Wekken-Pas^*
, Fabian Weiss
, Charlotte Simon-Zuber
, Rena Sebisch
, Carmen Wiese
, Elisabeth van Leeuwen
, David Burger
, Angela Colbers^*

^*Corresponding author for this work

Radboud University Nijmegen
Ludwig Maximilian University of Munich
MVZ Karlsplatz
Amsterdam UMC - University of Amsterdam

Research output: Contribution to journal › Article › Academic › peer-review

30 Downloads (Pure)

Abstract

This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.

Original language	English
Pages (from-to)	1468-1471
Journal	Clinical infectious diseases
Volume	79
Issue number	6
DOIs	https://doi.org/10.1093/cid/ciae242
Publication status	Published - 15 Dec 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being
SDG 5 Gender Equality

Access to Document

10.1093/cid/ciae242

Long-acting-injectable-cabotegravir-and-rilpivirine-in-a-pregnant-woman-with-hiv.pdfFinal published version, 364 KBLicence: CC BY

Cite this

@article{d3ac6cc612474a50a4f86d92e2c67237,

title = "Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV",

abstract = "This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70\%-75\% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.",

author = "\{van der Wekken-Pas\}, Lena and Fabian Weiss and Charlotte Simon-Zuber and Rena Sebisch and Carmen Wiese and \{van Leeuwen\}, Elisabeth and David Burger and Angela Colbers",

year = "2024",

month = dec,

day = "15",

doi = "10.1093/cid/ciae242",

language = "English",

volume = "79",

pages = "1468--1471",

journal = "Clinical infectious diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

AU - van der Wekken-Pas, Lena

AU - Weiss, Fabian

AU - Simon-Zuber, Charlotte

AU - Sebisch, Rena

AU - Wiese, Carmen

AU - van Leeuwen, Elisabeth

AU - Burger, David

AU - Colbers, Angela

PY - 2024/12/15

Y1 - 2024/12/15

N2 - This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.

AB - This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.

UR - https://www.scopus.com/pages/publications/85207167075

UR - https://www.ncbi.nlm.nih.gov/pubmed/38703388

U2 - 10.1093/cid/ciae242

DO - 10.1093/cid/ciae242

M3 - Article

C2 - 38703388

SN - 1058-4838

VL - 79

SP - 1468

EP - 1471

JO - Clinical infectious diseases

JF - Clinical infectious diseases

IS - 6

ER -

Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this